Tamoxifen, but not aromatase inhibitors, increases the risk for diabetes (15) and an in vivo study suggests that tamoxifen is associated with lower total IGF1R levels but higher phosphorylated IGF1R levels (16). Here, CYP19A1 is linked to diabetes mellitus.